insulin and semaglutide could remove need for injections in type 1 diabetes, promising study shows What are GLP-1 medications and

Due to FDA regulations, manufacturers cannot claim that their product cures, treats, or reduces the risk of a specific disease or condition unless it has been proven by research to do so ( However, they can include structural or functional claims, which describe how the ingredients in the product may affect systems or organs in your body ( For example, a supplement can say that it supports energy levels

Regen Ther 30:259267

Ongoing studies, such as the SOUL trial, are exploring the potential cardiovascular benefits of oral semaglutide in T2DM patients with established atherosclerotic cardiovascular disease and/or chronic kidney disease [50]

A study conducted in 2001 showed that CJC-1295 was safe and generally well tolerated in patients who received a 14-day regimen that was delivered subcutaneously

Possible FDA approval for the new drug is anticipated sometime in 2026 or 2027